Drug intelligence / Profile preview

hoslabconazole

Development stage: Unknown
Lead developer: SATO Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Hoslabconazole is an oral azole antifungal agent developed by Sato Pharmaceutical for the treatment of superficial fungal infections, including tinea pedis and onychomycosis. It exerts its therapeutic effect by inhibiting the enzyme lanosterol 14-alpha-demethylase (CYP51), which is critical for the biosynthesis of ergosterol, a vital component of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol intermediates lead to membrane dysfunction and inhibition of fungal growth. Hoslabconazole is currently being evaluated in late-stage clinical trials in Japan as a once-daily oral therapy, offering a systemic treatment option for dermatophytosis.

Other names: hoslabconazole

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on hoslabconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hoslabconazole.

Explore the full profile